Allergy Partners of N.J., P.C.

CURRENT STUDIES:

Sponsor: Novartis Pharmaceuticals
Protocol Number: CQGE031G12301
Protocol Title: A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab in decreasing the sensitivity to peanuts in patients with peanut allergy.
Ages: 6-55
ClinicalTrials.gov Identifier: NCT04984876

Sponsor: ALK Abello A/S
Protocol Number: PT-01
Protocol Title: A phase I open-label trial to assess the tolerability and safety of an up-dosing regimen with a once-daily peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Ages: 12-65
ClinicalTrials.gov Identifier: NCT05440643

Sponsor: Regeneron Pharmaceuticals
Protocol Number: R668-cSNP-2072
Protocol Title: Assessing long-term outcomes of Dupixent treatment in patients with chronic rhinosinusitis with nasal polyposis (AROMA)
Ages: 18 and older
ClinicalTrials.gov Identifier: NCT04959448

Sponsor: Regeneron Pharmaceuticals
Protocol Number: R668-AS-1885
Protocol Title: Registry of asthma patients initiating Dupixent (RAPID)
Ages: 12 and older
ClinicalTrials.gov Identifier: NCT04287621

Sponsor: Allergy Therapeutics
Protocol Number: PQGrass 306
Protocol Title: A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure.
Ages: 18-65
ClinicalTrials.gov Identifier: NCT05540717